乳岩宁方下调MCF-7荷瘤裸鼠HER-2基因表达及提高免疫功能的实验研究
|
摘要
目的:通过观察乳岩宁方对MCF-7乳腺癌荷瘤裸鼠HER-2/nue基因表达及对免疫功能的影响,探讨其对乳腺癌的抑瘤作用,并初步研究其作用机制。
材料与方法:将人乳腺癌细胞株MCF-7接种于BALB/C-nu/nu裸鼠右侧胸壁第二乳垫部皮下,选取荷瘤成功裸鼠随机分为对照组、乳岩宁组、平消胶囊组,每组9只。记录各组裸鼠精神状态、饮食、体重变化情况;第18天,处死裸鼠取脾、肿瘤,称重,计算脾指数、抑瘤率;制作透射电镜切片,透射电镜下病理形态学观察;Western Blotting检测肿瘤组织中HER-2/nue蛋白的表达。
结果:
1.乳岩宁方能改善荷瘤裸鼠生存质量,维持荷瘤裸鼠的体重,乳岩宁组体重净降明显低于对照组、平消胶囊组(p﹤0.01)。
2.乳岩宁组和平消胶囊组的瘤重均低于对照组,与对照组相比差异性显著(p﹤0.01)。
3.乳岩宁组的脾指数最高,与平消胶囊组相比差异性显著(p﹤0.05),与对照组相比无差异性显著(p>0.05)。
4.透射电镜观察结果显示乳岩宁方能够诱导MCF-7乳腺癌细胞凋亡。
5. HER-2/nue蛋白表达结果:乳岩宁组、平消胶囊组均低于对照组,与对照组比较差异性显著(p﹤0.05)。
结论:
1.乳岩宁方能改善MCF-7荷瘤裸鼠机体状况,提高生活质量。
2.乳岩宁方能提高MCF-7荷瘤裸鼠脾指数,可能提高了裸鼠的免疫功能。
3.乳岩宁方具有一定的抑瘤作用,可能通过诱导肿瘤细胞凋亡和抑制肿瘤组织中HER-2/nue基因蛋白的表达来实现的。
Purpose: The aim of this study is to observe the influence of Ruyanning Decoction to HER-2 gene and immune function in MCF-7 mammary cancer loaded on Nude mice and to investigate the tumor-inhibition function and action mechanism.
Material and method:BALB/C Nude mice are injected MCF-7 on the second breast pad of the right chest wall subcutaneously .Twenty seven mice were randomized into model group, Ruyanning group and Pingxiao group after inoculating MCF-7 cell. The conditions of drink and food, body weight and transplanted tumor weight were observed and recorded every other day , Spleen and tumor were taken and weighed when the mice were sacrificed in each group respectively on the eighth day. Then the inhibition rate of tumor and indices of spleen were calculated . All the tumor tissues were sliced and pathomorphological observed by transmission electron microscope (TEM).HER-2 protein expression of tumors tissues were detected by western blotting.
Results:
1. The decline of body weight in Ruyanning group were lower than the other two groups(p﹤0.01).
2. Tumor weight of model group was significantly higher than the other two groups (p <0.01).
3. The index of spleen in Ruyanning group was higher than Pingxiao group and the difference was significant(p﹤0.05).But comparing to the model group, there was no significant difference(p>0.05).
4. The tumor cell apoptosis of the MCF-7 breast cancer could be induced by Ruyanning Decoction.
5. The expreesion of HER-2 protein of the Ruyanning group and the Ping xiao group were both lower than the model group and the difference was signifi-cant (p﹤0.05).
Conclusion:
1. The prescription of Ruyanning can improve body status of mice.
2. The prescription of Ruyanning can enhance the index of spleen and improve immune function possibly.
3. The prescription of Ruyanning can inhibit tuomor to some extent and the possible mechanisms of which are induced apoptosis and down- regulate expression of HER-2.
材料与方法:将人乳腺癌细胞株MCF-7接种于BALB/C-nu/nu裸鼠右侧胸壁第二乳垫部皮下,选取荷瘤成功裸鼠随机分为对照组、乳岩宁组、平消胶囊组,每组9只。记录各组裸鼠精神状态、饮食、体重变化情况;第18天,处死裸鼠取脾、肿瘤,称重,计算脾指数、抑瘤率;制作透射电镜切片,透射电镜下病理形态学观察;Western Blotting检测肿瘤组织中HER-2/nue蛋白的表达。
结果:
1.乳岩宁方能改善荷瘤裸鼠生存质量,维持荷瘤裸鼠的体重,乳岩宁组体重净降明显低于对照组、平消胶囊组(p﹤0.01)。
2.乳岩宁组和平消胶囊组的瘤重均低于对照组,与对照组相比差异性显著(p﹤0.01)。
3.乳岩宁组的脾指数最高,与平消胶囊组相比差异性显著(p﹤0.05),与对照组相比无差异性显著(p>0.05)。
4.透射电镜观察结果显示乳岩宁方能够诱导MCF-7乳腺癌细胞凋亡。
5. HER-2/nue蛋白表达结果:乳岩宁组、平消胶囊组均低于对照组,与对照组比较差异性显著(p﹤0.05)。
结论:
1.乳岩宁方能改善MCF-7荷瘤裸鼠机体状况,提高生活质量。
2.乳岩宁方能提高MCF-7荷瘤裸鼠脾指数,可能提高了裸鼠的免疫功能。
3.乳岩宁方具有一定的抑瘤作用,可能通过诱导肿瘤细胞凋亡和抑制肿瘤组织中HER-2/nue基因蛋白的表达来实现的。
Purpose: The aim of this study is to observe the influence of Ruyanning Decoction to HER-2 gene and immune function in MCF-7 mammary cancer loaded on Nude mice and to investigate the tumor-inhibition function and action mechanism.
Material and method:BALB/C Nude mice are injected MCF-7 on the second breast pad of the right chest wall subcutaneously .Twenty seven mice were randomized into model group, Ruyanning group and Pingxiao group after inoculating MCF-7 cell. The conditions of drink and food, body weight and transplanted tumor weight were observed and recorded every other day , Spleen and tumor were taken and weighed when the mice were sacrificed in each group respectively on the eighth day. Then the inhibition rate of tumor and indices of spleen were calculated . All the tumor tissues were sliced and pathomorphological observed by transmission electron microscope (TEM).HER-2 protein expression of tumors tissues were detected by western blotting.
Results:
1. The decline of body weight in Ruyanning group were lower than the other two groups(p﹤0.01).
2. Tumor weight of model group was significantly higher than the other two groups (p <0.01).
3. The index of spleen in Ruyanning group was higher than Pingxiao group and the difference was significant(p﹤0.05).But comparing to the model group, there was no significant difference(p>0.05).
4. The tumor cell apoptosis of the MCF-7 breast cancer could be induced by Ruyanning Decoction.
5. The expreesion of HER-2 protein of the Ruyanning group and the Ping xiao group were both lower than the model group and the difference was signifi-cant (p﹤0.05).
Conclusion:
1. The prescription of Ruyanning can improve body status of mice.
2. The prescription of Ruyanning can enhance the index of spleen and improve immune function possibly.
3. The prescription of Ruyanning can inhibit tuomor to some extent and the possible mechanisms of which are induced apoptosis and down- regulate expression of HER-2.
引文
[1] Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2007 [ J ].CA Cancer Clin, 2007, 57 (1) : 43-66.
[2]A. BOTTOMLEY,P. THERASSE,M. PICCART. Health-related quality of life in survivors of locally advanced breast cancer: An international randomized controlled phase III trial[J].Lancet Oncol,2005,6(5):287-294.
[3]Cui Y, Shu XO, Gao Y,et al.Use of complementary and alternative medicine by Chinese women with breast cancer[J].Breast Cancer Res Treat,2004,85(3):263-270.
[4]冯磊,张莲芬,严婷等.中药虎杖中抗癌活性物质研究[J].中药材,2006,29(7): 689-691.
[5]Sliva Danie,Jiang Jiahua, Slivova Veronika etal, Natural terpenoids inhibit the proliferation and invasiveness of human breast. XVth World Congress of Pharmacology: Meeting Abstracts:338 cancer cells
[6]孙斌,瞿伟菁,柏忠江.蒺藜皂苷对乳腺癌细胞Bcap-37的体外抑制作用[J].中药材, 2003, 26(2): 104-106.
[7]吴少华,张仲海,赵建斌.补骨脂素体内外抗癌活性的实验研究[J].中国中药杂志, 19 98, 23(5): 303-305.
[8]李博,于庭,徐继杰.人参皂甙Rg3对乳腺癌细胞(MCF-7)表达金属蛋白酶2、9(MMP-2, MMP-9)的影响[J].中国实验诊断学, 2005, 9(4): 539-540.
[9]魏小龙,茹祥斌,刘福君,等.低分子量地黄多糖对癌基因表达的影响[J].中国药理与毒理学杂志,1998,12(2):159.
[10]盛新华,季锡清.芹黄素抗乳腺癌作用机制的研究进展[J].中国肿瘤临床, 2006, 33 (8):30.
[11]盛新华,卿三华,季锡清等.芹黄素对乳腺癌细胞株MCF-7,MDA-MB-435S的侵袭和增殖能力的影响[J].中华实验外科杂志,2006,23(4):629.
[12]张维文,黎银燕,张贵平,等.熊果酸诱导人乳腺癌细胞MCF-7凋亡的实验研究[J].中药材, 2005, 28(4): 297-300.
[13]戎煜,梁福佑,陈莉,等.去甲斑蝥素对人乳腺癌细胞系的凋亡诱导作用及bcl-2基因的表达[ J].癌症,2000, 19(12): 1077-1081.
[14]陈俊霞,夏俊,刘基巍.人参皂甙Rg3诱导乳腺癌细胞系MCF-7凋亡的实验研究[J].癌变.畸变.突变, 2005, 17(4): 213-216.
[15]李贵新,张玲,王芸,等.淫羊藿甙诱导肿瘤细胞凋亡及其机制〔J〕.中国肿瘤生物治疗杂志,1997,4(3):235.
[16]丁志山,高承贤,陈铌铍,等.姜黄素具有抑制血管生成与诱导肿瘤细胞凋亡双重作用.中国药理学通报,2003,19(2):171-173.
[17]谭成,俞惠新,林秀峰,等.中药逆转乳腺癌细胞多药耐药性的实验研究[J].中药药理与临床, 2005, 21(3): 32-34.
[18]胡凯文,候丽,陈信义,等.大黄酸/大黄素抗多药耐药肿瘤细胞研究[J].中国中医基础医学杂志, 1998, 4(11): 19.
[19]张晓丽,曹国宪,俞惠新,等.延胡索乙素逆转多药耐药性人乳腺癌细胞MCF-7[ J].中药药理与临床,2005, 21(6): 19-21.
[20]Plouzek CA,CiolinoH P, ClarkeR, et al .Inhibition of P-glycopro-tein ac- tivity and reversal ofmultidmg resistancein vitro by se-maryextract[ J]. Eur J Cancer, 1999, 35(10): 1541.
[21]刘叙仪,孟松粮,杨敬贤,等.中药R3(补骨脂抽提剂)对耐阿霉素人乳腺癌细胞MCF-7多药耐药的逆转[J].中国肿瘤临床, 1997, 24(5): 325.
[22]王金华,叶祖光,孙爱续,等.粉防己碱逆转人乳腺癌MCF-7多药耐药细胞的抗凋亡作用[J].中国中药杂志,2002,27(1):46～50.
[23]王玉华,赵谨瑶,等.雄黄对硫化砷多药耐药的逆转及机制研究[J].解剖科学进展,2003,9(2):135～138.
[24]陆长虹,李杰,郭伟剑,等.大黄素对乳腺癌多药耐药细胞株MCF-7/ADR的耐药逆转作用[J].临床肿瘤学杂志,2004,9(4):3401～343.
[25]胡军,赵瑾瑶,杨佩满.β-榄香烯乳剂逆转多药耐药细胞株MCF-7/ADM对阿霉素耐药性研究[J].中国微生态学杂志,2002,14(4):214-215.
[26]安达勇.十全大补汤作为支持疗法对进行性乳腺癌的疗效研究[J].国外医学·中医中药分册,1991,13(4):46-47.
[27]花宝金.肿瘤虚证及扶正培本治疗的现代免疫机制研究[J].中国中医基础医学志, 2000,6(3):60.
[28]余素清,刘京生,韩彩芝.复方绞股蓝提高乳腺癌患者NK细胞活性[J].中医药究, 1997,13(4):7-8.
[29]曹志然,周文英,陈淑兰,等.十全大补汤对小鼠免疫功能影响的实验研究[J] .中国中医基础医学杂志;2000,6(10):34-35.
[30]曹志然,周文英,陈淑兰,等.十全大补汤对荷瘤鼠脾细胞增殖、IL-6及TNF-α水平的影响[J].上海免疫学杂志,2002,22(6):370.
[31]曹志然,韩艳梅,戎瑞雪,等.十全大补汤对移植乳腺癌小鼠免疫抑瘤作用的实验研究[J].时珍国医国药,2007,18(4):1025-1026.
[32]韩艳梅,曹志然,王晓辉,等.十全大补汤对移植乳腺癌小鼠化疗的减毒增效作用[J].军医进修学院学报,2007,28(5):358-359.
[33]邹奎昌,徐凤仙,林水淼,等.养阴方和清解方治大鼠肝脏癌变的超微结构改变[J].上海中医药杂志,1996,(7):45.
[34]刘胜,陆德铭.“乳宁冲剂”抑制DMBA诱导大鼠乳腺癌的实验研究[J].亚洲医药,1997,(1):26.
[35]吴雪卿,刘胜,高尚璞,等.乳宁Ⅱ号对MCF-7实验研究移植瘤的抑瘤作用及对乳腺癌相关蛋白的影响[J].中国中西医结合外科杂志, 2004, 10(2): 99-102.
[36]松崎佑子.小柴胡汤及其成分对细胞凋亡的诱导作用[J].国外医学·中医药学分册,1996,18(6):36.
[37]王蓉蓉,殷玉志,刘素宾.补肾化瘀药对HL-60细胞凋亡的诱导作用[J].中国中医药信息杂志,1998,5(5):24.
[38]吴雪卿,高尚璞,牟明春,等.乳宁Ⅱ号对TA2小鼠乳腺癌MA-891移植瘤中血管内皮生长因子表达的影响[J].中国中西医结合杂志,2004,24(3):251-253.
[39]阙华发,高尚璞,陈红风,等.乳宁Ⅱ号对乳腺癌MA-891细胞株生长转移的影响[J].上海中医药大学学报,2001,15(4):42-44.
[40]阙华发,高尚璞,陈红风,等.乳宁Ⅱ号对人乳腺癌MDA-MB-435细胞株生长转移的影响[J].中国中医基础医学杂志,2002,8(7):32-34.
[41]陈前军,陆德铭,刘胜,等.中药乳宁Ⅱ号对Ca761小鼠移植性乳腺癌的抑制作用[J].实用肿瘤学杂志,1999, 13(4): 243-244.
[42]陈前军,张策,陆德铭,等.“乳宁Ⅱ号”对Ca761小鼠移植性乳腺癌移植瘤细胞分化的影响[J].中国中医基础医学杂志, 2001, 7(8):34-36.
[43]陈前军,王一安,司徒红林,等.乳宁Ⅱ号方对小鼠Ca761乳腺癌移植瘤细胞周期及p53和ras表达的影响[J].中西医结合学报,2005,3(3):225-227.
[44]陈前军,司徒红林,陆德铭,等.乳宁Ⅱ号对Ca761小鼠乳腺癌增殖及细胞凋亡的影响[J].新中医,2008,40(6):100-101.
[45]陈前军,陆德铭,司徒红林,等. "乳宁Ⅱ号"抑制Ca761小鼠乳腺癌肺转移及其对nm23、Cath-D表达的影响[J].中国中医基础医学杂志,2007,13(7):523-524.
[46]刘胜,花永强,杨新伟,等.乳移平对不同乳腺癌肺转移动物模型VEGF蛋白表达和MVD计数影响的研究[J].上海中医药杂志2007, 41(3):11-13.
[47] Veronesi V,Cascinelli N,Mariani L,et al.Twenty-year follow-up of a randomized study comparing breast-conserving surgery withradical mastectomy for early breast cancer[J].N Engl J Med,2002,347(16):1227-1232.
[48]Fisher B,Anderson S,Bryant J,et al.Twenty-year follow-up of arandomized trial comparing total mastectomy,lumpectomy,andlumpectomy plus irradiation for the treatment of breast cancer[J].N Engl J Med,2002,347(16):1233-1241.
[49]Reed J,Rosman M,Verbanac KM,et al. Prognostic implications of isolated tumor cells and micro-metastases in sentinel nodes of patients with invasive breast cancer:10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multi center Study[J].J Am Coll Surg,2009,208(3):333-340.
[50]刘鹏熙,林毅,陈前军,等.乳腺癌围手术期中医药参与治疗的若干问题探讨[J].中西医结合学报,2005,3(3):178-180.
[51]宾湘义.中药对乳腺癌根治术围手术期微量元素的影响[J].浙江中西医结合杂志, 2004, 11(2):86-87.
[52]罗雪冰,李良,刘南梅,等.扶正抗癌汤治疗乳腺癌术后疗效观察[J].辽宁中医杂志,2007,34(9):1288-1289.
[53]罗雪冰,李良,刘南梅,等.中医药治疗乳腺癌术后患者疗效观察[J].中国中医急症,2008,17(6):770-771.
[54]蔡炳,郭勤,郭智涛,等.生肌玉红膏对乳腺癌术后皮瓣坏死疡的疗效观察[J].中医外治杂志, 1997,(5):11.
[55]王骁.张新渝老师治疗乳腺癌根治术后单纯性上肢肿胀经验介绍[J].新中医, 2006,38(2):17-18.
[56]陈鹊汀,胡耕坤.桃红四物汤治疗乳腺癌术后皮瓣血运障碍40例[J].河北职工医学院学报, 2003, 20(1):29
[57]孙贻安.血府逐瘀胶囊防治乳腺癌术后并发症的临床观察[J].山东中医药大学学报, 2003,27(1):39
[58]孙鲁.复方丹参注射液静滴防治乳腺癌术后并发症的临床观察[J].山东医药1999,3 9(24):55.
[59]陈海滨,应声闻.血府逐瘀汤预防乳腺癌术后皮瓣坏死体会[J].现代中西医结合志, 2008,17(5):731.
[60]郭智涛,司徒红林,突出中医外治法治疗乳腺癌之我见[J].天津中医,2001,18(4): 44.
[61]温建余,李铁.玉桂膏治疗乳腺癌术后皮瓣坏死21例疗效观察[J].新中医,2002, 34 (3): 21.
[62]温建余,李铁,鲁明,等.自拟玉桂膏治疗乳腺癌手术后皮瓣坏死72例[J].陕西中医,2002,23(3):199-200.
[63]钟少文,江慧玲.滑石粉治疗乳腺癌术后淋巴漏32例[J].中医外治杂志,2004,13(2): 54.
[64]孙德娟,黄克江,鲍维珍.生肌玉红膏治疗乳腺癌术后皮瓣坏死26例体会[J].黑龙江医学,2006,30(3):553.
[65]史耀华.美宝湿润烧伤膏掺药外治乳癌术后皮瓣坏死21例[J].现代中医,1999,4(8) :19.
[66]王长宏.二妙散加味外敷治疗乳腺癌术后皮瓣不愈19例[J].浙江中医杂志2006,41(5):272.
[67]廖明娟,蒉纲,王永灵等.紫归长皮膏治疗乳腺癌术后皮瓣坏死创面不愈的临床研究[J].上海中医药杂志,2009,43(11):43-44.
[68]宋滨东,张秀卿,张杰,等.湿润烧伤膏预防乳腺癌术后皮瓣坏死的临床研究[J].中国现代医药杂志,2007,9(3):81-82.
[69]周月芬.补阳还五汤加味治疗乳腺癌术后上肢肿胀疗效观察[J].河北中医, 2000, 22(2):129.
[70]郑武,邹荣生.血府逐瘀汤加减结合功能锻炼治疗乳腺癌术后上肢水肿30例[J].福建中医药, 2004, 35(3):30.
[71]王福文,朱燕,胡志力.桑叶片的药效学研究[J].时珍国医药,2004,15(2):65-67.
[72]樊晓滨.活血化瘀法治疗乳腺癌根治术后并发症41例[J].国医论坛,2004,18(4):28
[73]吴玉华,万冬桂.当归芍药散加味治疗乳腺癌术后同侧上肢肿胀38例[J].中医药学报,2003,31(1):45.
[74]黎汉忠,黄智芬,张作军.电针配合复方丹参注射液治疗乳腺癌术后上肢淋巴水肿的临床观察[J].河北中医,2002,24(4):255-257.
[75]樊凤英,周松阳.补阳还五汤加减治疗乳腺癌术后上肢水肿19例体会[J].甘肃中医, 2002,15(6):25.
[76]谢丹,杨海燕.乳癌消肿汤治疗乳腺癌术后患侧上肢肿胀23例[J].新中医,2006,38 (8):69.
[77]龚蔚.四妙勇安汤加减治疗乳腺癌术后上肢水肿验案举隅[J].南京中医药大学报,2 006,22(4):257-258.
[78]王晓露,潘宇,戴虹.通络化瘀汤治疗乳腺癌术后上肢肿胀56例临床观察[J].临床肿瘤学杂志,2008,13(10):935-936.
[79]王维志,桂明亮,董洪荣,等.中西医结合治疗乳腺癌术后上肢淋巴水肿[J].世界中西医结合杂志,2009,4(8):576-577.
[80]刘胜,花永强,孙虎平,等.乳移平抗乳腺癌术后复发转移的临床研究[J].中西医结合学报, 2007, 5(2):147-149.
[81]刘胜,谭松,花永强等.乳移平抗乳腺癌术后复发转移的临床随机对照试验[C].山东:山东中医药学会外科专业委员会,2008:126-131.
[82]沈晔华,宋明志,黄雯霞.中西医结合治疗71例乳腺癌术后患者的疗效分析[J].中西医结合学报, 2003, 1(1): 30-31..
[83]向丽萍,欧阳恒.菊藻丸抗乳腺癌术后复发转移的临床观察[ J].中药临床药理学与治疗, 2002, 7(1):63-64.
[84]李仕金.乳腺癌系统治疗与生存关系的探讨[J].中国中医中药信息杂志, 2006, 13 (5):79-80.
[85]喻伟国,程进明.抗癌汤结合化疗治疗肿瘤术后48例总结[ J].湖南中医志,2003,19 (1):11-13.
[86]陈前军,司徒红林,周劬志,等.乳宁Ⅱ号抗乳腺癌短期复发转移的临床研究[ J].现代中西医结合杂志,2002,11(16):1546-1548.
[87]贾喜花.乳宁Ⅱ号对乳腺癌术后患者血清中VEGF、TNF-a、INF-r影响的研究[J].中医药学刊, 2005, 23(8): 1430-1431.
[88]刘胜,赵婧,刘佳,等.乳癌术后方对乳腺癌术后5年复发转移率的影响[ J].中西医结合学报, 2008, 6(10): 1000-1004.
[89]孙燕.内科肿瘤学[M ].北京:人民卫生出版社,2001: 90.
[90]徐立宁,苗艳艳,丁志强,等.参芪扶正注射液对乳腺癌术后化疗的影响[J].河南医药信息, 2003, 24(1):12.
[91]陈芳,林红.参芪扶正注射液辅助乳癌化疗的疗效观察[J].海峡药学. 2007,19(12): 75-76.
[92]韩娅.健脾益肾中药防治乳腺癌放疗血液毒性作用的观察[J].中医药临床杂志2005, l7(1):15-16.
[93]张宏,李国康.增髓汤对乳腺癌术后化疗改善骨髓抑制的研究[J].实用医学杂志, 20 05, 2l(13):1481-1482.
[94]陈长怀.中西医结合治疗乳腺癌42例临床观察[J].浙江中西医结合杂志, 2001,11 (2): 81.
[95]朱华宇,司徒红林.林毅辨治乳腺癌经验撷菁[J].辽宁中医杂志,2007,34(4):395- 396.
[96]翁永强,唐汉钧,程爱群,等.扶正祛邪法改善乳腺癌患者化疗毒副作用的临床观察[J].上海中医药大学学报, 2003, 17(3):28-31.
[97]黄智芬,韦劲松,施智严,等.八珍汤加味配合化疗治疗中晚期乳腺癌的研究[J].现代中西医结合杂志, 2003,12(11):1123-1124.
[98]唐汉钧,高尚璞,等.中医药治疗乳腺癌术后患者288例临床观察[J].上海中医药大学学报,2002,16(3):23-25..
[99]谭开基,曹洋.陈锐深辨治晚期乳腺癌的方法与思路[J].上海中医药杂志,2005,39 (7):17-18.
[100]洪宋贞,林毅,司徒红林,等.龟鹿二仙丹加味治疗乳腺癌化疗后骨髓抑制的临床研究[J].新中医,2005,37(1):32-33.
[101]范钰,杨兆民,万铭,等.针灸防治恶性肿瘤化疗毒副反应的临床研究[J].上海针灸杂志,2001,20(1):12-14.
[102]梁少华,李敏江,李廷冠.升血和中汤防治乳腺癌术后化疗毒副反应临床观察[J].广西中医药,2002,25(4):8-9.
[103]李洪胜,王远东,何伟星,等.地榆升白片预防乳腺癌患者新辅助化疗后外周血细胞下降的临床研究[J].中国基层医药,2005,12(4):397-398.
[104]卢雯平,陈长怀,花宝金,等.乳腺癌的中医治疗思路及方法[J].中国肿瘤,2003,12 (6):331-333.
[105]秦海洗.唐汉钧教授治疗乳腺癌辨证思路与用药经验[J].中西医结合学报,2004,2 (4):297—298.
[106]李云菁,李志革,等.四磨汤治疗化疗所致的胃肠道症状27例总结[J].湖南中医杂志,1997,13(4):5.
[107]王亚非,姚祖培,黄新中,等.旋覆代赭汤加味防治恶性肿瘤化疗呕吐反应的临床研究[J].中国中西医结合杂志,1998,18(5):273.
[108]陈群雄.针灸中药治疗介入后呕吐60例观察[J].新中医,1998,7:20.
[109]杨丽萍,孙士玲.中药配合术前化疗治疗乳腺癌临床研究[J].河南中医学院学报, 2004,4(19): 40.
[110]任渐平,李先明,吴超权等.参芪扶正注射液对乳腺癌术后放疗保护作用的临床观察[J].中医药学报,2005,20(5):32-33.
[111]周浩本.中药防治乳腺癌化疗消化道反应[J].医药产业资讯, 2005, 2(11): 63.
[112]司徒红林,林毅,陈前军,等.中药癌复康对乳腺癌术后化疗患者生存质量的影[J].广州中医药大学学报,2005,22(1):26~29.
[113]何元凤.穴位按压配合心理护理对减轻乳腺癌化疗患者恶心呕吐的观察[J].广西医学,2006,28(5):738—739.
[114]尚可,乔俊红,王庆书,等.中药对乳腺癌术后化疗患者生存质量的影响[J].中医中药,2008,5(35):69-70.
[115]郝淑芳.中药配合来曲唑治疗晚期乳腺癌临床观察[J].中医药学刊, 2004, 22(11): 2089.
[116]樊帆.平消胶囊综合治疗晚期乳腺癌疗效评价(附136例临床分析) [J].陕西肿瘤医学,2001,9(4):291.
[117]张清,赵文辉,来玉娟,等.平消胶囊联合内分泌药物治疗或化疗对晚期乳腺癌的影响[J].中国中西医结合杂志2005,25(12):1074-1076.
[118]马翠翠.六味地黄丸预防乳腺癌患者服用芳香化酶抑制剂所致骨量丢失的临床研究[D].福州:福建中医学院,2009,4-16.
[119]李宁.二仙汤加味防治芳香化酶抑制剂所致乳腺癌患者骨丢失的临床观察[D].北京:北京中医药大学,2009,16-18.
[120]朱紫青,季健林,肖世富.抑郁障碍诊疗关键[M].南京:江苏科学技术出版社,2003,2(3),221-225.
[121]欧阳卫平,陈德玉,初玲等.妇科肿瘤患者放疗或化疗后的抑郁症状和生活质量的调查分析[J].中国实用护理杂志2004,20(12):56-57.
[122]陈良珠,谢忠.乳腺癌患者的焦虑抑郁情绪测定及其中医对策[J].齐齐哈尔医学院学报,2002,23(8):886-887.
[123]秦海光.唐汉钧教授治疗乳腺癌辨证思路与用药经验[J].中西医结合学报,2004,2(4):297-298.
[124]倪爱娣,吴丽英.辨证分型治疗乳腺癌术后情志异常100例[J].上海中医志,1999, (11):23.
[125]刘龙,秦志丰.二仙汤为主治疗乳腺癌治疗后出现类更年期综合征35例[J].浙江中医杂志,2004,39(02):75.
[126]张瑶,沈伟生.加味二仙汤治疗乳腺癌综合治疗后类更年期综合征32例[J].山东中医药大学学报,2007,31(2):137-138.
[127]张晓丽,伯洁,王爱蓉.旱莲草汤缓解乳腺癌内分泌治疗不良反应52例[J].吉林中医药,2004,24(4):22.
[128]孙琛.逍遥二仙汤治疗乳腺癌相关性类围绝经期综合征症状群的临床研究[D].山东:山东中医药大学,2009:2-13.
[1]邢向荣,殷东风.运用柴胡剂从肝论治提高恶性肿瘤患者生存质量的临床分析[J].实用中医内科杂志,2007,21(1):58-59
[2]朱颖,殷东风.中医药提高肿瘤患者生存质量的研究进展[J].医学综述,2006,12(8): 504-505
[3]甄林林,武正炎,范萍,等.人乳腺癌裸鼠移植模型的建立[J].南京医科大学学报,2001,(11):509-510.
[4]徐淑云主编.药理实验方法学[M].北京:人民卫生出版, 2002: 203.
[5]白淑红,殷东风.乳岩宁血清合用阿霉素干预乳腺癌HER-2癌基因的实验研究[J].临床肿瘤学杂志,2006,11(7):491-493.
[6]吴少华,张仲海,赵建斌.补骨脂素体内外抗癌活性的实验研究[J].中国中药杂志, 1998, 23(5): 303-305.
[7]戎煜,梁福佑,陈莉,等.去甲斑蝥素对人乳腺癌细胞系的凋亡诱导作用及bcl-2基因的表达[ J].癌症,2000, 19(12): 1077-1081.
[8]张维文,黎银燕,张贵平,等.熊果酸诱导人乳腺癌细胞MCF-7凋亡的实验研究[J].中药材, 2005, 28(4): 297-300 .
[9]陈俊霞,夏俊,刘基巍.人参皂甙Rg3诱导乳腺癌细胞系MCF-7凋亡的实验研究[J].癌变.畸变.突变, 2005, 17(4): 213-216.
[10]Hsu YL, Kuo PL, Chiang LC, et al.Involvement of p53, nuclear factor kappa B and Fas/Fas ligand in induction of apoptosis and cell cycle arrest by Sai- kosaponin d in human hepatoma cell lines [J].CancerLett,2004,213(2):213-221.
[11]Hsu YL, Kuo PL, Lin CC. The proliferative inhibition and apoptotic mechanism of Saikosaponin D in human non-small cell lung cancer A549 cells [J].Life Sci, 2004,75(10):1231-1242.
[12]Chen JC, Chang NW, Chung JG, et al. Saikosaponin -A induces apoptotic me- chanism in human breast MDA-MB-231 and MCF-7cancer cells [J].Am J Chin Med, 2003,31(3):363-377.
[13]Pegram M D, Psuletti G, Slamon D J.HER-2/neu as a predictive marker of response to breast cancer therapy [J].Breast Caner Res Treat,1998,52(1-3):765-772.
[14]Geisler S, Lonning P E, Aas T, et al.Influence of TP 53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer[J].Cancer Res,2001,6(6):2505-2512.
[15] Tovey S, Dunne B, Witton GJ, et al. Can molecular markers predict when to Implement treatment with aromatase inhibitors in invasive breast cancer [J].Clin Cancer Res,2005,11(12):4835-4842.
[16]Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in post menopausal women after five years of tamoxifen therapy for early-stage breast cancer[J].N Engl JMed,2003,349(19):1793-1802.
[17]Orr MS,O’Connor PM, Kohn KW,et al. Effects of c-erbB-2 overexpression on the drug sensitivities of normal human mammary epithelial cells[J].J Natl Cancer Inst,2000,92(12):987-994.
[18]Menard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node- positive breast cancer according to HER2 overexpression and other tumor biologic variables[J].J Clin Oncol,2001, 19(2):329-335.
[19]Iish I, Harada M, Azuma K, et al. HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA2A2+cancer patients[J].Int J Oncol,2004,24(4):9672-9751.
[20]Yang HP. Clinical therapeutic efficacy observation on chemotherapy combined Pingxiao capsule in treatment of middle-stage or advanced non-small cell lung cancer. Shanxi Oncol Med 2002,1(10):60-61.
[21]李工.平消胶囊配合化疗治疗肺癌初步临床疗效分析[J].现代肿瘤学,2004,12(1): 62-63.
[22]谭晓云,李金彩.平消胶囊联合化疗治疗晚期非小细胞肺癌临床观察[J].湖北中医杂志,2005,27(4):29.
[23]李豫江,李志刚,吴涛.乳腺癌术前行平消胶囊联合化疗疗效观察[J].现代肿瘤医学, 2005,13(2):29.
[24]刘健,赵韬,谢佐福等.平消胶囊抗肿瘤分子的生物学机制[J].福建医科大学报,2006,40(4):369-372.
[25]周立江,殷东风,潘玉珍等.肺积宁对C57小鼠肺癌VEGF蛋白表达和生存质量的影响[J].现代肿瘤医学,2009,17(6):1042-1045.
[26]孙燕,林洪生,朱允中等.长春瑞滨合并顺铂(NP)加参一胶囊或安慰剂治疗晚期非小细胞肺癌的多中心双盲随机临床研究报告[J].中国肺癌杂志,2006,9(3):254-258.
[27]林小聪,刘新光陈小文等.黄芩甙对重组人蛋白激酶CK2全酶的抑制作用及其动力学分析[J].癌症,2004,23(8):874-878.
[28]唐广义,殷东风.肠积宁方促进大肠癌细胞株HT-29凋亡及干预相关基因bcl-2及bax表达的实验研究[J].现代肿瘤学,2007,15(4):491-493.
[2]A. BOTTOMLEY,P. THERASSE,M. PICCART. Health-related quality of life in survivors of locally advanced breast cancer: An international randomized controlled phase III trial[J].Lancet Oncol,2005,6(5):287-294.
[3]Cui Y, Shu XO, Gao Y,et al.Use of complementary and alternative medicine by Chinese women with breast cancer[J].Breast Cancer Res Treat,2004,85(3):263-270.
[4]冯磊,张莲芬,严婷等.中药虎杖中抗癌活性物质研究[J].中药材,2006,29(7): 689-691.
[5]Sliva Danie,Jiang Jiahua, Slivova Veronika etal, Natural terpenoids inhibit the proliferation and invasiveness of human breast. XVth World Congress of Pharmacology: Meeting Abstracts:338 cancer cells
[6]孙斌,瞿伟菁,柏忠江.蒺藜皂苷对乳腺癌细胞Bcap-37的体外抑制作用[J].中药材, 2003, 26(2): 104-106.
[7]吴少华,张仲海,赵建斌.补骨脂素体内外抗癌活性的实验研究[J].中国中药杂志, 19 98, 23(5): 303-305.
[8]李博,于庭,徐继杰.人参皂甙Rg3对乳腺癌细胞(MCF-7)表达金属蛋白酶2、9(MMP-2, MMP-9)的影响[J].中国实验诊断学, 2005, 9(4): 539-540.
[9]魏小龙,茹祥斌,刘福君,等.低分子量地黄多糖对癌基因表达的影响[J].中国药理与毒理学杂志,1998,12(2):159.
[10]盛新华,季锡清.芹黄素抗乳腺癌作用机制的研究进展[J].中国肿瘤临床, 2006, 33 (8):30.
[11]盛新华,卿三华,季锡清等.芹黄素对乳腺癌细胞株MCF-7,MDA-MB-435S的侵袭和增殖能力的影响[J].中华实验外科杂志,2006,23(4):629.
[12]张维文,黎银燕,张贵平,等.熊果酸诱导人乳腺癌细胞MCF-7凋亡的实验研究[J].中药材, 2005, 28(4): 297-300.
[13]戎煜,梁福佑,陈莉,等.去甲斑蝥素对人乳腺癌细胞系的凋亡诱导作用及bcl-2基因的表达[ J].癌症,2000, 19(12): 1077-1081.
[14]陈俊霞,夏俊,刘基巍.人参皂甙Rg3诱导乳腺癌细胞系MCF-7凋亡的实验研究[J].癌变.畸变.突变, 2005, 17(4): 213-216.
[15]李贵新,张玲,王芸,等.淫羊藿甙诱导肿瘤细胞凋亡及其机制〔J〕.中国肿瘤生物治疗杂志,1997,4(3):235.
[16]丁志山,高承贤,陈铌铍,等.姜黄素具有抑制血管生成与诱导肿瘤细胞凋亡双重作用.中国药理学通报,2003,19(2):171-173.
[17]谭成,俞惠新,林秀峰,等.中药逆转乳腺癌细胞多药耐药性的实验研究[J].中药药理与临床, 2005, 21(3): 32-34.
[18]胡凯文,候丽,陈信义,等.大黄酸/大黄素抗多药耐药肿瘤细胞研究[J].中国中医基础医学杂志, 1998, 4(11): 19.
[19]张晓丽,曹国宪,俞惠新,等.延胡索乙素逆转多药耐药性人乳腺癌细胞MCF-7[ J].中药药理与临床,2005, 21(6): 19-21.
[20]Plouzek CA,CiolinoH P, ClarkeR, et al .Inhibition of P-glycopro-tein ac- tivity and reversal ofmultidmg resistancein vitro by se-maryextract[ J]. Eur J Cancer, 1999, 35(10): 1541.
[21]刘叙仪,孟松粮,杨敬贤,等.中药R3(补骨脂抽提剂)对耐阿霉素人乳腺癌细胞MCF-7多药耐药的逆转[J].中国肿瘤临床, 1997, 24(5): 325.
[22]王金华,叶祖光,孙爱续,等.粉防己碱逆转人乳腺癌MCF-7多药耐药细胞的抗凋亡作用[J].中国中药杂志,2002,27(1):46～50.
[23]王玉华,赵谨瑶,等.雄黄对硫化砷多药耐药的逆转及机制研究[J].解剖科学进展,2003,9(2):135～138.
[24]陆长虹,李杰,郭伟剑,等.大黄素对乳腺癌多药耐药细胞株MCF-7/ADR的耐药逆转作用[J].临床肿瘤学杂志,2004,9(4):3401～343.
[25]胡军,赵瑾瑶,杨佩满.β-榄香烯乳剂逆转多药耐药细胞株MCF-7/ADM对阿霉素耐药性研究[J].中国微生态学杂志,2002,14(4):214-215.
[26]安达勇.十全大补汤作为支持疗法对进行性乳腺癌的疗效研究[J].国外医学·中医中药分册,1991,13(4):46-47.
[27]花宝金.肿瘤虚证及扶正培本治疗的现代免疫机制研究[J].中国中医基础医学志, 2000,6(3):60.
[28]余素清,刘京生,韩彩芝.复方绞股蓝提高乳腺癌患者NK细胞活性[J].中医药究, 1997,13(4):7-8.
[29]曹志然,周文英,陈淑兰,等.十全大补汤对小鼠免疫功能影响的实验研究[J] .中国中医基础医学杂志;2000,6(10):34-35.
[30]曹志然,周文英,陈淑兰,等.十全大补汤对荷瘤鼠脾细胞增殖、IL-6及TNF-α水平的影响[J].上海免疫学杂志,2002,22(6):370.
[31]曹志然,韩艳梅,戎瑞雪,等.十全大补汤对移植乳腺癌小鼠免疫抑瘤作用的实验研究[J].时珍国医国药,2007,18(4):1025-1026.
[32]韩艳梅,曹志然,王晓辉,等.十全大补汤对移植乳腺癌小鼠化疗的减毒增效作用[J].军医进修学院学报,2007,28(5):358-359.
[33]邹奎昌,徐凤仙,林水淼,等.养阴方和清解方治大鼠肝脏癌变的超微结构改变[J].上海中医药杂志,1996,(7):45.
[34]刘胜,陆德铭.“乳宁冲剂”抑制DMBA诱导大鼠乳腺癌的实验研究[J].亚洲医药,1997,(1):26.
[35]吴雪卿,刘胜,高尚璞,等.乳宁Ⅱ号对MCF-7实验研究移植瘤的抑瘤作用及对乳腺癌相关蛋白的影响[J].中国中西医结合外科杂志, 2004, 10(2): 99-102.
[36]松崎佑子.小柴胡汤及其成分对细胞凋亡的诱导作用[J].国外医学·中医药学分册,1996,18(6):36.
[37]王蓉蓉,殷玉志,刘素宾.补肾化瘀药对HL-60细胞凋亡的诱导作用[J].中国中医药信息杂志,1998,5(5):24.
[38]吴雪卿,高尚璞,牟明春,等.乳宁Ⅱ号对TA2小鼠乳腺癌MA-891移植瘤中血管内皮生长因子表达的影响[J].中国中西医结合杂志,2004,24(3):251-253.
[39]阙华发,高尚璞,陈红风,等.乳宁Ⅱ号对乳腺癌MA-891细胞株生长转移的影响[J].上海中医药大学学报,2001,15(4):42-44.
[40]阙华发,高尚璞,陈红风,等.乳宁Ⅱ号对人乳腺癌MDA-MB-435细胞株生长转移的影响[J].中国中医基础医学杂志,2002,8(7):32-34.
[41]陈前军,陆德铭,刘胜,等.中药乳宁Ⅱ号对Ca761小鼠移植性乳腺癌的抑制作用[J].实用肿瘤学杂志,1999, 13(4): 243-244.
[42]陈前军,张策,陆德铭,等.“乳宁Ⅱ号”对Ca761小鼠移植性乳腺癌移植瘤细胞分化的影响[J].中国中医基础医学杂志, 2001, 7(8):34-36.
[43]陈前军,王一安,司徒红林,等.乳宁Ⅱ号方对小鼠Ca761乳腺癌移植瘤细胞周期及p53和ras表达的影响[J].中西医结合学报,2005,3(3):225-227.
[44]陈前军,司徒红林,陆德铭,等.乳宁Ⅱ号对Ca761小鼠乳腺癌增殖及细胞凋亡的影响[J].新中医,2008,40(6):100-101.
[45]陈前军,陆德铭,司徒红林,等. "乳宁Ⅱ号"抑制Ca761小鼠乳腺癌肺转移及其对nm23、Cath-D表达的影响[J].中国中医基础医学杂志,2007,13(7):523-524.
[46]刘胜,花永强,杨新伟,等.乳移平对不同乳腺癌肺转移动物模型VEGF蛋白表达和MVD计数影响的研究[J].上海中医药杂志2007, 41(3):11-13.
[47] Veronesi V,Cascinelli N,Mariani L,et al.Twenty-year follow-up of a randomized study comparing breast-conserving surgery withradical mastectomy for early breast cancer[J].N Engl J Med,2002,347(16):1227-1232.
[48]Fisher B,Anderson S,Bryant J,et al.Twenty-year follow-up of arandomized trial comparing total mastectomy,lumpectomy,andlumpectomy plus irradiation for the treatment of breast cancer[J].N Engl J Med,2002,347(16):1233-1241.
[49]Reed J,Rosman M,Verbanac KM,et al. Prognostic implications of isolated tumor cells and micro-metastases in sentinel nodes of patients with invasive breast cancer:10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multi center Study[J].J Am Coll Surg,2009,208(3):333-340.
[50]刘鹏熙,林毅,陈前军,等.乳腺癌围手术期中医药参与治疗的若干问题探讨[J].中西医结合学报,2005,3(3):178-180.
[51]宾湘义.中药对乳腺癌根治术围手术期微量元素的影响[J].浙江中西医结合杂志, 2004, 11(2):86-87.
[52]罗雪冰,李良,刘南梅,等.扶正抗癌汤治疗乳腺癌术后疗效观察[J].辽宁中医杂志,2007,34(9):1288-1289.
[53]罗雪冰,李良,刘南梅,等.中医药治疗乳腺癌术后患者疗效观察[J].中国中医急症,2008,17(6):770-771.
[54]蔡炳,郭勤,郭智涛,等.生肌玉红膏对乳腺癌术后皮瓣坏死疡的疗效观察[J].中医外治杂志, 1997,(5):11.
[55]王骁.张新渝老师治疗乳腺癌根治术后单纯性上肢肿胀经验介绍[J].新中医, 2006,38(2):17-18.
[56]陈鹊汀,胡耕坤.桃红四物汤治疗乳腺癌术后皮瓣血运障碍40例[J].河北职工医学院学报, 2003, 20(1):29
[57]孙贻安.血府逐瘀胶囊防治乳腺癌术后并发症的临床观察[J].山东中医药大学学报, 2003,27(1):39
[58]孙鲁.复方丹参注射液静滴防治乳腺癌术后并发症的临床观察[J].山东医药1999,3 9(24):55.
[59]陈海滨,应声闻.血府逐瘀汤预防乳腺癌术后皮瓣坏死体会[J].现代中西医结合志, 2008,17(5):731.
[60]郭智涛,司徒红林,突出中医外治法治疗乳腺癌之我见[J].天津中医,2001,18(4): 44.
[61]温建余,李铁.玉桂膏治疗乳腺癌术后皮瓣坏死21例疗效观察[J].新中医,2002, 34 (3): 21.
[62]温建余,李铁,鲁明,等.自拟玉桂膏治疗乳腺癌手术后皮瓣坏死72例[J].陕西中医,2002,23(3):199-200.
[63]钟少文,江慧玲.滑石粉治疗乳腺癌术后淋巴漏32例[J].中医外治杂志,2004,13(2): 54.
[64]孙德娟,黄克江,鲍维珍.生肌玉红膏治疗乳腺癌术后皮瓣坏死26例体会[J].黑龙江医学,2006,30(3):553.
[65]史耀华.美宝湿润烧伤膏掺药外治乳癌术后皮瓣坏死21例[J].现代中医,1999,4(8) :19.
[66]王长宏.二妙散加味外敷治疗乳腺癌术后皮瓣不愈19例[J].浙江中医杂志2006,41(5):272.
[67]廖明娟,蒉纲,王永灵等.紫归长皮膏治疗乳腺癌术后皮瓣坏死创面不愈的临床研究[J].上海中医药杂志,2009,43(11):43-44.
[68]宋滨东,张秀卿,张杰,等.湿润烧伤膏预防乳腺癌术后皮瓣坏死的临床研究[J].中国现代医药杂志,2007,9(3):81-82.
[69]周月芬.补阳还五汤加味治疗乳腺癌术后上肢肿胀疗效观察[J].河北中医, 2000, 22(2):129.
[70]郑武,邹荣生.血府逐瘀汤加减结合功能锻炼治疗乳腺癌术后上肢水肿30例[J].福建中医药, 2004, 35(3):30.
[71]王福文,朱燕,胡志力.桑叶片的药效学研究[J].时珍国医药,2004,15(2):65-67.
[72]樊晓滨.活血化瘀法治疗乳腺癌根治术后并发症41例[J].国医论坛,2004,18(4):28
[73]吴玉华,万冬桂.当归芍药散加味治疗乳腺癌术后同侧上肢肿胀38例[J].中医药学报,2003,31(1):45.
[74]黎汉忠,黄智芬,张作军.电针配合复方丹参注射液治疗乳腺癌术后上肢淋巴水肿的临床观察[J].河北中医,2002,24(4):255-257.
[75]樊凤英,周松阳.补阳还五汤加减治疗乳腺癌术后上肢水肿19例体会[J].甘肃中医, 2002,15(6):25.
[76]谢丹,杨海燕.乳癌消肿汤治疗乳腺癌术后患侧上肢肿胀23例[J].新中医,2006,38 (8):69.
[77]龚蔚.四妙勇安汤加减治疗乳腺癌术后上肢水肿验案举隅[J].南京中医药大学报,2 006,22(4):257-258.
[78]王晓露,潘宇,戴虹.通络化瘀汤治疗乳腺癌术后上肢肿胀56例临床观察[J].临床肿瘤学杂志,2008,13(10):935-936.
[79]王维志,桂明亮,董洪荣,等.中西医结合治疗乳腺癌术后上肢淋巴水肿[J].世界中西医结合杂志,2009,4(8):576-577.
[80]刘胜,花永强,孙虎平,等.乳移平抗乳腺癌术后复发转移的临床研究[J].中西医结合学报, 2007, 5(2):147-149.
[81]刘胜,谭松,花永强等.乳移平抗乳腺癌术后复发转移的临床随机对照试验[C].山东:山东中医药学会外科专业委员会,2008:126-131.
[82]沈晔华,宋明志,黄雯霞.中西医结合治疗71例乳腺癌术后患者的疗效分析[J].中西医结合学报, 2003, 1(1): 30-31..
[83]向丽萍,欧阳恒.菊藻丸抗乳腺癌术后复发转移的临床观察[ J].中药临床药理学与治疗, 2002, 7(1):63-64.
[84]李仕金.乳腺癌系统治疗与生存关系的探讨[J].中国中医中药信息杂志, 2006, 13 (5):79-80.
[85]喻伟国,程进明.抗癌汤结合化疗治疗肿瘤术后48例总结[ J].湖南中医志,2003,19 (1):11-13.
[86]陈前军,司徒红林,周劬志,等.乳宁Ⅱ号抗乳腺癌短期复发转移的临床研究[ J].现代中西医结合杂志,2002,11(16):1546-1548.
[87]贾喜花.乳宁Ⅱ号对乳腺癌术后患者血清中VEGF、TNF-a、INF-r影响的研究[J].中医药学刊, 2005, 23(8): 1430-1431.
[88]刘胜,赵婧,刘佳,等.乳癌术后方对乳腺癌术后5年复发转移率的影响[ J].中西医结合学报, 2008, 6(10): 1000-1004.
[89]孙燕.内科肿瘤学[M ].北京:人民卫生出版社,2001: 90.
[90]徐立宁,苗艳艳,丁志强,等.参芪扶正注射液对乳腺癌术后化疗的影响[J].河南医药信息, 2003, 24(1):12.
[91]陈芳,林红.参芪扶正注射液辅助乳癌化疗的疗效观察[J].海峡药学. 2007,19(12): 75-76.
[92]韩娅.健脾益肾中药防治乳腺癌放疗血液毒性作用的观察[J].中医药临床杂志2005, l7(1):15-16.
[93]张宏,李国康.增髓汤对乳腺癌术后化疗改善骨髓抑制的研究[J].实用医学杂志, 20 05, 2l(13):1481-1482.
[94]陈长怀.中西医结合治疗乳腺癌42例临床观察[J].浙江中西医结合杂志, 2001,11 (2): 81.
[95]朱华宇,司徒红林.林毅辨治乳腺癌经验撷菁[J].辽宁中医杂志,2007,34(4):395- 396.
[96]翁永强,唐汉钧,程爱群,等.扶正祛邪法改善乳腺癌患者化疗毒副作用的临床观察[J].上海中医药大学学报, 2003, 17(3):28-31.
[97]黄智芬,韦劲松,施智严,等.八珍汤加味配合化疗治疗中晚期乳腺癌的研究[J].现代中西医结合杂志, 2003,12(11):1123-1124.
[98]唐汉钧,高尚璞,等.中医药治疗乳腺癌术后患者288例临床观察[J].上海中医药大学学报,2002,16(3):23-25..
[99]谭开基,曹洋.陈锐深辨治晚期乳腺癌的方法与思路[J].上海中医药杂志,2005,39 (7):17-18.
[100]洪宋贞,林毅,司徒红林,等.龟鹿二仙丹加味治疗乳腺癌化疗后骨髓抑制的临床研究[J].新中医,2005,37(1):32-33.
[101]范钰,杨兆民,万铭,等.针灸防治恶性肿瘤化疗毒副反应的临床研究[J].上海针灸杂志,2001,20(1):12-14.
[102]梁少华,李敏江,李廷冠.升血和中汤防治乳腺癌术后化疗毒副反应临床观察[J].广西中医药,2002,25(4):8-9.
[103]李洪胜,王远东,何伟星,等.地榆升白片预防乳腺癌患者新辅助化疗后外周血细胞下降的临床研究[J].中国基层医药,2005,12(4):397-398.
[104]卢雯平,陈长怀,花宝金,等.乳腺癌的中医治疗思路及方法[J].中国肿瘤,2003,12 (6):331-333.
[105]秦海洗.唐汉钧教授治疗乳腺癌辨证思路与用药经验[J].中西医结合学报,2004,2 (4):297—298.
[106]李云菁,李志革,等.四磨汤治疗化疗所致的胃肠道症状27例总结[J].湖南中医杂志,1997,13(4):5.
[107]王亚非,姚祖培,黄新中,等.旋覆代赭汤加味防治恶性肿瘤化疗呕吐反应的临床研究[J].中国中西医结合杂志,1998,18(5):273.
[108]陈群雄.针灸中药治疗介入后呕吐60例观察[J].新中医,1998,7:20.
[109]杨丽萍,孙士玲.中药配合术前化疗治疗乳腺癌临床研究[J].河南中医学院学报, 2004,4(19): 40.
[110]任渐平,李先明,吴超权等.参芪扶正注射液对乳腺癌术后放疗保护作用的临床观察[J].中医药学报,2005,20(5):32-33.
[111]周浩本.中药防治乳腺癌化疗消化道反应[J].医药产业资讯, 2005, 2(11): 63.
[112]司徒红林,林毅,陈前军,等.中药癌复康对乳腺癌术后化疗患者生存质量的影[J].广州中医药大学学报,2005,22(1):26~29.
[113]何元凤.穴位按压配合心理护理对减轻乳腺癌化疗患者恶心呕吐的观察[J].广西医学,2006,28(5):738—739.
[114]尚可,乔俊红,王庆书,等.中药对乳腺癌术后化疗患者生存质量的影响[J].中医中药,2008,5(35):69-70.
[115]郝淑芳.中药配合来曲唑治疗晚期乳腺癌临床观察[J].中医药学刊, 2004, 22(11): 2089.
[116]樊帆.平消胶囊综合治疗晚期乳腺癌疗效评价(附136例临床分析) [J].陕西肿瘤医学,2001,9(4):291.
[117]张清,赵文辉,来玉娟,等.平消胶囊联合内分泌药物治疗或化疗对晚期乳腺癌的影响[J].中国中西医结合杂志2005,25(12):1074-1076.
[118]马翠翠.六味地黄丸预防乳腺癌患者服用芳香化酶抑制剂所致骨量丢失的临床研究[D].福州:福建中医学院,2009,4-16.
[119]李宁.二仙汤加味防治芳香化酶抑制剂所致乳腺癌患者骨丢失的临床观察[D].北京:北京中医药大学,2009,16-18.
[120]朱紫青,季健林,肖世富.抑郁障碍诊疗关键[M].南京:江苏科学技术出版社,2003,2(3),221-225.
[121]欧阳卫平,陈德玉,初玲等.妇科肿瘤患者放疗或化疗后的抑郁症状和生活质量的调查分析[J].中国实用护理杂志2004,20(12):56-57.
[122]陈良珠,谢忠.乳腺癌患者的焦虑抑郁情绪测定及其中医对策[J].齐齐哈尔医学院学报,2002,23(8):886-887.
[123]秦海光.唐汉钧教授治疗乳腺癌辨证思路与用药经验[J].中西医结合学报,2004,2(4):297-298.
[124]倪爱娣,吴丽英.辨证分型治疗乳腺癌术后情志异常100例[J].上海中医志,1999, (11):23.
[125]刘龙,秦志丰.二仙汤为主治疗乳腺癌治疗后出现类更年期综合征35例[J].浙江中医杂志,2004,39(02):75.
[126]张瑶,沈伟生.加味二仙汤治疗乳腺癌综合治疗后类更年期综合征32例[J].山东中医药大学学报,2007,31(2):137-138.
[127]张晓丽,伯洁,王爱蓉.旱莲草汤缓解乳腺癌内分泌治疗不良反应52例[J].吉林中医药,2004,24(4):22.
[128]孙琛.逍遥二仙汤治疗乳腺癌相关性类围绝经期综合征症状群的临床研究[D].山东:山东中医药大学,2009:2-13.
[1]邢向荣,殷东风.运用柴胡剂从肝论治提高恶性肿瘤患者生存质量的临床分析[J].实用中医内科杂志,2007,21(1):58-59
[2]朱颖,殷东风.中医药提高肿瘤患者生存质量的研究进展[J].医学综述,2006,12(8): 504-505
[3]甄林林,武正炎,范萍,等.人乳腺癌裸鼠移植模型的建立[J].南京医科大学学报,2001,(11):509-510.
[4]徐淑云主编.药理实验方法学[M].北京:人民卫生出版, 2002: 203.
[5]白淑红,殷东风.乳岩宁血清合用阿霉素干预乳腺癌HER-2癌基因的实验研究[J].临床肿瘤学杂志,2006,11(7):491-493.
[6]吴少华,张仲海,赵建斌.补骨脂素体内外抗癌活性的实验研究[J].中国中药杂志, 1998, 23(5): 303-305.
[7]戎煜,梁福佑,陈莉,等.去甲斑蝥素对人乳腺癌细胞系的凋亡诱导作用及bcl-2基因的表达[ J].癌症,2000, 19(12): 1077-1081.
[8]张维文,黎银燕,张贵平,等.熊果酸诱导人乳腺癌细胞MCF-7凋亡的实验研究[J].中药材, 2005, 28(4): 297-300 .
[9]陈俊霞,夏俊,刘基巍.人参皂甙Rg3诱导乳腺癌细胞系MCF-7凋亡的实验研究[J].癌变.畸变.突变, 2005, 17(4): 213-216.
[10]Hsu YL, Kuo PL, Chiang LC, et al.Involvement of p53, nuclear factor kappa B and Fas/Fas ligand in induction of apoptosis and cell cycle arrest by Sai- kosaponin d in human hepatoma cell lines [J].CancerLett,2004,213(2):213-221.
[11]Hsu YL, Kuo PL, Lin CC. The proliferative inhibition and apoptotic mechanism of Saikosaponin D in human non-small cell lung cancer A549 cells [J].Life Sci, 2004,75(10):1231-1242.
[12]Chen JC, Chang NW, Chung JG, et al. Saikosaponin -A induces apoptotic me- chanism in human breast MDA-MB-231 and MCF-7cancer cells [J].Am J Chin Med, 2003,31(3):363-377.
[13]Pegram M D, Psuletti G, Slamon D J.HER-2/neu as a predictive marker of response to breast cancer therapy [J].Breast Caner Res Treat,1998,52(1-3):765-772.
[14]Geisler S, Lonning P E, Aas T, et al.Influence of TP 53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer[J].Cancer Res,2001,6(6):2505-2512.
[15] Tovey S, Dunne B, Witton GJ, et al. Can molecular markers predict when to Implement treatment with aromatase inhibitors in invasive breast cancer [J].Clin Cancer Res,2005,11(12):4835-4842.
[16]Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in post menopausal women after five years of tamoxifen therapy for early-stage breast cancer[J].N Engl JMed,2003,349(19):1793-1802.
[17]Orr MS,O’Connor PM, Kohn KW,et al. Effects of c-erbB-2 overexpression on the drug sensitivities of normal human mammary epithelial cells[J].J Natl Cancer Inst,2000,92(12):987-994.
[18]Menard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node- positive breast cancer according to HER2 overexpression and other tumor biologic variables[J].J Clin Oncol,2001, 19(2):329-335.
[19]Iish I, Harada M, Azuma K, et al. HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA2A2+cancer patients[J].Int J Oncol,2004,24(4):9672-9751.
[20]Yang HP. Clinical therapeutic efficacy observation on chemotherapy combined Pingxiao capsule in treatment of middle-stage or advanced non-small cell lung cancer. Shanxi Oncol Med 2002,1(10):60-61.
[21]李工.平消胶囊配合化疗治疗肺癌初步临床疗效分析[J].现代肿瘤学,2004,12(1): 62-63.
[22]谭晓云,李金彩.平消胶囊联合化疗治疗晚期非小细胞肺癌临床观察[J].湖北中医杂志,2005,27(4):29.
[23]李豫江,李志刚,吴涛.乳腺癌术前行平消胶囊联合化疗疗效观察[J].现代肿瘤医学, 2005,13(2):29.
[24]刘健,赵韬,谢佐福等.平消胶囊抗肿瘤分子的生物学机制[J].福建医科大学报,2006,40(4):369-372.
[25]周立江,殷东风,潘玉珍等.肺积宁对C57小鼠肺癌VEGF蛋白表达和生存质量的影响[J].现代肿瘤医学,2009,17(6):1042-1045.
[26]孙燕,林洪生,朱允中等.长春瑞滨合并顺铂(NP)加参一胶囊或安慰剂治疗晚期非小细胞肺癌的多中心双盲随机临床研究报告[J].中国肺癌杂志,2006,9(3):254-258.
[27]林小聪,刘新光陈小文等.黄芩甙对重组人蛋白激酶CK2全酶的抑制作用及其动力学分析[J].癌症,2004,23(8):874-878.
[28]唐广义,殷东风.肠积宁方促进大肠癌细胞株HT-29凋亡及干预相关基因bcl-2及bax表达的实验研究[J].现代肿瘤学,2007,15(4):491-493.